SGN-35, an antibody-drug conjugate, is in an ongoing pivotal trial under a special protocol assessment from the FDA for relapsed or refractory Hodgkin lymphoma. The designation allows the
Ixiaro was developed to provide a well-tolerated, effective and convenient vaccine against Japanese encephalitis (JE), suitable for administration to travelers who wish to reduce their risk of acquiring
The topiramate tablets are therapeutically equivalent to Topamax tablets from Ortho-McNeil Janssen Pharmaceuticals and are available in four strengths: 25mg, 50mg, 100mg and 200mg. Topiramate is indicated as
The placement was led by Forbion Capital Partners, who were joined by other existing investors including Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science
Dr Jochelson and Mr Levin will serve in integral roles managing clinical programs and licensing/partnership agreements for BrainCells’s pipeline of neurologic compounds. Dr Jochelson will replace Steve Targum
A previous licensing agreement covering Europe, Russia, the Middle East, North Africa, Latin America and Canada was signed in January 2009. Under the terms of the agreement, EffRx
Mr Whitnell will work in this capacity under the oversight of the special committee of the board of directors until a new CEO is named. As the company
Gilead Sciences, a biopharmaceutical company, has started enrolling patients in a Phase II clinical trial of cicletanine hydrochloride, an oral agent in development for the treatment of pulmonary
The alliance seeks to increase productivity in drug discovery and development by synergizing the unique strengths of both companies. The collaborative research program may continue for a span
Mr Hamm has been executive vice president of pharmaceutical operations and technology at the company since 2007. As COO, Mr Hamm will add global business operations to his
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.